Deciphering the Exposome by Metabolomic Technology in Breast Cancer

EXPOMET aims to revolutionize understanding of environmental contaminants and their role in breast cancer through innovative mass spectrometry-based exposome assessment and high-throughput monitoring.

Subsidie
€ 2.937.489
2023

Projectdetails

Introduction

EXPOMET proposes a pioneering mass spectrometry-based platform for omic-scale assessment of chemical exposures. EXPOMET will revolutionize our perception of environmental contaminants and the influence these have on breast cancer (BC).

Background

In our ageing society, the incidence of chronic disease is constantly rising; yet, environmental drivers of disease susceptibility are poorly understood. Measuring the myriad of chemicals that humans are constantly exposed to is immensely challenging; and identifying interactions and the molecular pathways that are disrupted is an even more complex task.

To address this issue, the concept of the exposome, i.e., the totality of chemical exposures and the biological effects thereof, was proposed. Innovative analytical technology, however, is lacking and remains the major limitation in this emerging field.

Objectives

EXPOMET aims to establish new avenues towards a comprehensive sequencing of the exposome and illuminating the role played in the etiology of BC. Affecting 1 in 8, BC is the most common cancer in European women.

Methodology

Novel workflows will overcome current limitations and enable high-throughput exposure and effect monitoring of a vast number of environmentally relevant chemicals. The developed cutting-edge methods will be applied, and critically evaluated, in the first exposome-wide association (ExWAS) study on BC.

A deeper understanding of the toxicological impact of co-exposure will be obtained from ensuing functional, systems-level experiments. Breakthrough metabolomic-guided pathway mapping and activity-screening technology will be utilized for investigating causative events.

Impact

The project will provide unique insights into the impact of chemical exposure on the etiology of BC and ground-breaking exposomic technology. EXPOMET will revolutionize viewpoints on environmental contaminants and the influence these have on chronic disease.

Expertise

The PI has a uniquely interdisciplinary expertise to address the multi-facets of this exposome approach.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.937.489
Totale projectbegroting€ 2.937.489

Tijdlijn

Startdatum1-3-2023
Einddatum29-2-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • UNIVERSITAT WIENpenvoerder

Land(en)

Austria

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Functional characterization of the colorectal cancer metastasis microbiome

The METABAC project aims to investigate the functional roles of bacteria in colorectal cancer metastasis using innovative platforms to uncover their impact on cancer progression and potential therapeutic targets.

€ 1.499.894
ERC Starting...

Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and Diagnosis

EpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors.

€ 1.500.000
ERC Starting...

Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomics

The CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms.

€ 2.481.640
ERC Proof of...

Epigenetic profiling of menstrual blood for precision cancer detection and prevention

The EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers.

€ 150.000
ERC Starting...

Spatial Quantification of Cellular Metabolism in the Tumor Immune Microenvironment

This project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment.

€ 1.497.756

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

DETACT - Detection of Enzymes and muTAtions for Cancer Treatment

Cytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen.

€ 215.845
EIC Pathfinder

Remote SWEATSkin PATCH for Monitoring Breast Cancer Therapeutic Response

SWEATPATCH aims to develop a non-invasive, real-time monitoring system using sweat VOCs to personalize breast cancer treatment and improve patient outcomes through innovative technology.

€ 2.670.933